On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Namir is VP of the Infectious Diseases organisation and a member of the management team at Immunocore Ltd. In his time at the company, Namir has been responsible for building the biology and translational organisation to deliver novel immunotherapies, based on the company’s platform technology, into early phase trials. Namir has also been overseeing the first in human trial with the first in class IMCgp100 immunotherapy for the treatment of malignant melanoma and, is now overseeing the company’s Infectious Diseases Unit. Prior to joining Immunocore in April 2009, Namir was a Group Leader at GSK within Discovery Research, delivering novel assays for the screening of compounds targeting a variety of disease indications. Namir received his DPhil from the Cellular Immunology Unit at the University of Oxford, and has given talks, authored papers and book chapters on the application of immunotherapies to cancers and infectious diseases.
